Pittis Maria Gabriela, Montalvo Anna Lisa E, Miocic Snjezana, Martini Cristina, Deganuto Marta, Candusso Manila, Ciana Giovanni, Bembi Bruno
Unità Operativa Dipartimentale di Malattie Metaboliche, I.R.C.S.S. Burlo Garofolo, Trieste, Italy.
Am J Med Genet A. 2003 Sep 1;121A(3):225-30. doi: 10.1002/ajmg.a.20164.
Glycogen storage disease type II (GSDII) is an autosomal recessive disorder due to the deficiency of the lysosomal enzyme acid alpha glucosidase. Four novel mutations (C670T, G989A, G2188T, and Delta 23 nt 828-850) were identified in five Italian patients with the infantile form of the disease. The C670T mutation was present in two unrelated patients in heterozygosity; the effect on enzyme activity was assessed by in vitro expression. COS-1 cells expressing the C670T allele had a twofold higher activity than the negative control cells. The G989A and G2188T point mutations lead to the introduction of premature stop signals that results in truncated forms of alpha glucosidase. The in vitro expression of G2188T allele demonstrated no increment in activity compared to negative control. The frame shifting deletion of nucleotides 828-850 was identified in one patient in heterozygosity. The shift in the reading frame introduces a stop codon 135 nucleotides downstream the deletion junction that results in a truncated protein without catalytic activity. Nested PCR screening showed that the mutation was carried by the mother and was absent in the other members of the family. The four novel severe mutations herein described concerned only infantile onset GSDII patients; the loss of enzyme activity is correlated with the severity of the disease.
II型糖原贮积病(GSDII)是一种常染色体隐性疾病,由溶酶体酶酸性α-葡萄糖苷酶缺乏所致。在五名患有婴儿型该疾病的意大利患者中鉴定出四个新的突变(C670T、G989A、G2188T和828 - 850位核苷酸缺失23个)。C670T突变存在于两名无亲缘关系的杂合子患者中;通过体外表达评估其对酶活性的影响。表达C670T等位基因的COS - 1细胞活性比阴性对照细胞高两倍。G989A和G2188T点突变导致提前引入终止信号,从而产生截短形式的α-葡萄糖苷酶。与阴性对照相比,G2188T等位基因的体外表达未显示活性增加。在一名杂合子患者中鉴定出828 - 850位核苷酸的移码缺失。阅读框的移位在缺失连接处下游135个核苷酸处引入一个终止密码子,导致产生一种无催化活性的截短蛋白。巢式PCR筛查显示该突变由母亲携带,家族其他成员未携带。本文描述的这四个新的严重突变仅涉及婴儿期发病的GSDII患者;酶活性的丧失与疾病的严重程度相关。